The ongoing BRIDGET (NCT05323955) trial is a single-arm, phase 2, multicenter study that is evaluating the addition of tucatinib to trastuzumab/pertuzumab or trastuzumab emtansine after local therapy in patients with HER2+ metastatic breast cancer (MBC) with isolated brain relapse or progression. Read More ›

Findings of a small multi-institution retrospective study do not indicate a clear increased risk for interstitial lung disease with sequential treatment of antibody–drug conjugates in patients with metastatic breast cancer (MBC). Read More ›

Findings of a retrospective single-institution study indicates that higher body mass index (BMI) was associated with better survival outcomes compared with lower BMI in patients with metastatic/recurrent breast cancer. Read More ›

The DESTINY-Breast-RESPOND trial is a multicenter, prospective, observational study of trastuzumab deruxtecan that is evaluating the effectiveness and tolerability of trastuzumab deruxtecan in patients with HER2+ or HER2-low unresectable and/or metastatic breast cancer (MBC) in a real-world setting. Read More ›

Real-world evidence from a single-center experience showed that pertuzumab was well tolerated in older patients with HER2+ breast cancer in the real-world setting; however, a quarter of patients discontinued treatment due to toxicities. Read More ›

Page 2 of 2

Conference Correspondent Coverage is Brought to You by the Publishers of:
Oncology Practice Management
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications